A detailed history of Royal Bank Of Canada transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 8,914 shares of EWTX stock, worth $249,770. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,914
Previous 7,573 17.71%
Holding current value
$249,770
Previous $136,000 74.26%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.88 - $29.5 $21,295 - $39,559
1,341 Added 17.71%
8,914 $237,000
Q2 2024

Aug 14, 2024

BUY
$15.08 - $21.23 $84,161 - $118,484
5,581 Added 280.17%
7,573 $136,000
Q1 2024

Nov 05, 2024

SELL
$9.25 - $19.97 $51,624 - $111,452
-5,581 Reduced 73.7%
1,992 $36,000
Q1 2024

May 15, 2024

SELL
$9.25 - $19.97 $111,851 - $241,477
-12,092 Reduced 85.86%
1,992 $36,000
Q4 2023

Feb 14, 2024

BUY
$5.51 - $12.1 $34,062 - $74,802
6,182 Added 78.23%
14,084 $154,000
Q3 2023

Nov 14, 2023

BUY
$5.73 - $7.69 $15,688 - $21,055
2,738 Added 53.02%
7,902 $45,000
Q2 2023

Aug 14, 2023

BUY
$5.71 - $10.29 $13,355 - $24,068
2,339 Added 82.8%
5,164 $40,000
Q1 2023

May 15, 2023

SELL
$6.66 - $11.33 $10,303 - $17,527
-1,547 Reduced 35.38%
2,825 $18,000
Q4 2022

Feb 14, 2023

BUY
$7.58 - $11.08 $23,952 - $35,012
3,160 Added 260.73%
4,372 $39,000
Q3 2022

Nov 14, 2022

BUY
$8.08 - $13.58 $1,567 - $2,634
194 Added 19.06%
1,212 $12,000
Q2 2022

Aug 15, 2022

SELL
$5.67 - $9.87 $12,525 - $21,802
-2,209 Reduced 68.45%
1,018 $8,000
Q1 2022

May 16, 2022

SELL
$9.1 - $18.97 $113,067 - $235,702
-12,425 Reduced 79.38%
3,227 $31,000
Q4 2021

Feb 14, 2022

BUY
$14.41 - $22.41 $205,356 - $319,364
14,251 Added 1017.2%
15,652 $239,000
Q3 2021

Nov 15, 2021

BUY
$14.11 - $24.1 $7,859 - $13,423
557 Added 66.0%
1,401 $24,000
Q2 2021

Aug 16, 2021

BUY
$21.33 - $30.25 $18,002 - $25,531
844 New
844 $18,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.77B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.